Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Altered Endothelial Cells Properties and Platelets Activity in Treatment NaïVe Patients with Multiple Myeloma (MM ) and Non-Hodgkin Lymphoma (nHL): Association with Thromboembolic Complications

Lidia Usnarska-Zubkiewicz, prof., Maria Podolak-Dawidziak, prof., Urszula Zaleska-Dorobisz, prof., Magdalena Olszewska-Szopa, MD, Iwona Prajs, Jakub Debski, MD, Kazimierz Kuliczkowski, prof., Tadeusz Robak, MD PhD

Blood (2016) 128 (22): 5649.

https://doi.org/10.1182/blood.V128.22.5649.5649

Published: 2016

Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Blood (2016) 128 (22): 2978.

https://doi.org/10.1182/blood.V128.22.2978.2978

Published: 2016

Journal Articles

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Blood (2016) 128 (5): 630–637.

https://doi.org/10.1182/blood-2016-01-687434

Published: 2016

Includes: Supplemental data

Journal Articles

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

Blood (2016) 127 (3): 360–362.

https://doi.org/10.1182/blood-2015-08-662130

Published: 2016

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Tadeusz Robak, MD Professor, Krzysztof Warzocha, MD PhD, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, MD PhD, Javier Loscertales, Iryna Kryachok, Janusz Kloczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Blonski, Astrid McKeown, PhD, Chai-Ni Chang, Stephanie C Manson, Steen Lisby, Ira V. Gupta, MD, Sebastian Grosicki, MD PhD

Blood (2015) 126 (23): 5288.

https://doi.org/10.1182/blood.V126.23.5288.5288

Published: 2015

Journal Articles

Hasford Score Is Correlated with 18 Month Molecular Response for Chronic Myeloid Leukemia Patients Treated with Second Generation Tyrosine Kinase Inhibitors and It May be Useful to Differentiate Low and Intermediate Risk Patients: A Single Institution Experience

Jaroslaw Dybko, Olga Haus, MD, Bozena Jazwiec, Tomasz Lonc, Mateusz Sawicki, Kazimierz Kuliczkowski

Blood (2015) 126 (23): 5163.

https://doi.org/10.1182/blood.V126.23.5163.5163

Published: 2015

Journal Articles

Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results

Marinus H.J. van Oers, Kazimierz Kuliczkowski, MD PhD Prof., Lukas Smolej, Mario Petrini, Fritz Offner, Sebastian Gorsicki, Mark-David Levin, Ira Gupta, Jennifer Phillips, Vanessa Williams, Steen Lisby, Christian Geisler

Blood (2014) 124 (21): 21.

https://doi.org/10.1182/blood.V124.21.21.21

Published: 2014

Journal Articles

The Hasford Score Correlates with the Long-Term Molecular Response to Imatinib Treatment for Chronic Myeloid Leukemia Patients and May be Useful for Differentiating Low and Intermediate Risk Patients: A Single Institution Experience

Jaroslaw Dybko, MD PhD, Ewa Medras, MD, Olga Haus, MD PhD, Bozena Jazwiec, MSC, Tomasz Wrobel, MDPhD, Kazimierz Kuliczkowski, MD PhD Prof.

Blood (2014) 124 (21): 3152.

https://doi.org/10.1182/blood.V124.21.3152.3152

Published: 2014

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B

Kaan Kavakli, Lynne Smith, Kazimierz Kuliczkowski, MD PhD Prof., Joan Korth-Bradley, Chur Woo You, Joanne Fuiman, Silva Zupancic-Salek, Faraizah Abdul Karim, Pablo Rendo

Blood (2014) 124 (21): 1523.

https://doi.org/10.1182/blood.V124.21.1523.1523

Published: 2014

Journal Articles

Impact of Anthracycline-Based Induction Chemotherapy on the Calreticulin, CD47 Exposure and the Percentage of Regulatory T Cells in Patients with Acute Leukemias: Preliminary Study

Jakub Debski, MD, Lidia Usnarska-Zubkiewicz, Prof., Kazimierz Kuliczkowski

Blood (2014) 124 (21): 5259.

https://doi.org/10.1182/blood.V124.21.5259.5259

Published: 2014

Journal Articles

High Expression of Mir-15a Predicts Shorter Survival and Worse Response to Chemotherapy in Patients with Acute Myeloid Leukemia (AML)

Aleksandra Butrym, MD PhD, Dagmara Baczynska, PhD, Andrzej Tukiendorf, Prof., Justyna Rybka, MD PhD, Tadeusz Dobosz, Prof., Wojciech Jurczak, Kazimierz Kuliczkowski, MD PhD Prof., Grzegorz Mazur, Prof.

Blood (2014) 124 (21): 5330.

https://doi.org/10.1182/blood.V124.21.5330.5330

Published: 2014

Journal Articles

Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA)

Ruben A. Mesa, MD, Jorge E. Cortes, MD, Francisco Cervantes, MD, Donald Milligan, MD, FRCP, FRCPath, Tamás Masszi, MD, PhD, Elena Mishchenko, MD, Eric Jourdan, MD PhD, Alessandro M. Vannucchi, MD, Mark Drummond, MD PhD, Mindaugas Jurgutis, MD, Kazimierz Kuliczkowski, Professor, Emanuil Gheorghita, MD, Francesco Passamonti, MD, Frank Neumann, Florence Joulain, MSc, Sheikh Usman Iqbal, MD MPH MBA, Claire N Harrison, DM, FRCP, FRCPath

Blood (2013) 122 (21): 4061.

https://doi.org/10.1182/blood.V122.21.4061.4061

Published: 2013

Journal Articles

CD117 (c-kit) Expression On CD34+ Cells Participates In The Cytogenetic Response To Imatinib In CML Patients In First Chronic Phase

Jaroslaw Dybko, MD PhD, Ewa Medras, MD, Olga Haus, MD, PhD, Prof., Bozena Jazwiec, MSC, Joanna Urbaniak, PhD, Mieczyslaw Wozniak, PhD Prof., Kazimierz Kuliczkowski, Professor

Blood (2013) 122 (21): 3990.

https://doi.org/10.1182/blood.V122.21.3990.3990

Published: 2013

Journal Articles

Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group

Lidia Usnarska-Zubkiewicz, Jakub Debski, MD, Aleksandra K. Butrym, MD, PhD, Wojciech Legiec, Marek Hus, MD, PhD, Anna Dmoszynska, Beata Stella-Holowiecka, MD, Jan M Zaucha, Marcin Rymko, MD, Tigran Torosian, MD, Grzegorz Charlinski, Ewa Lech-Maranda, Artur J. Jurczyszyn, MD, PhD, Halina Urbanska-Rys, Agnieszka Druzd-Sitek, PhD, Kazimierz Kuliczkowski

Blood (2013) 122 (21): 3236.

https://doi.org/10.1182/blood.V122.21.3236.3236

Published: 2013

Journal Articles

A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis

Tadeusz Robak, Jerzy Z. Blonski, MD, PhD, Krzysztof Jamroziak, MD, PhD, Aleksander Skotnicki, Professor, Magdalena Piotrowska, MD, Anatoly Uss, Professor, Janusz Kloczko, Professor, Jaroslaw Piszcz, Kazimierz Kuliczkowski, Professor, Tomasz Wrobel, MD PhD, Bozena Katarzyna Budziszewska, MD, PhD, Marta Fidecka, Piotr Smolewski, Professor

Blood (2013) 122 (21): 1640.

https://doi.org/10.1182/blood.V122.21.1640.1640

Published: 2013

Journal Articles

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Animesh Pardanani, MBBS, PhD, Claire N Harrison, DM, FRCP, FRCPath, Jorge E. Cortes, MD, Francisco Cervantes, MD, Ruben A. Mesa, MD, Donald Milligan, MD, FRCP, FRCPath, Tamás Masszi, MD, PhD, Elena Mishchenko, MD, Eric Jourdan, MD PhD, Alessandro M. Vannucchi, MD, Mark Drummond, MD PhD, Mindaugas Jurgutis, MD, Kazimierz Kuliczkowski, Emanuil Gheorghita, MD, Francesco Passamonti, MD, Frank Neumann, Guozhi Gao, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 393.

https://doi.org/10.1182/blood.V122.21.393.393

Published: 2013

Journal Articles

Daunorubicine, Cytarabine and Cladribine (DAC) Vs Daunorubicine and Cytarabine (DA) Induction Treatment in Elderly Acute Myeloid Leukemia (AML) Patients – Results of the Prospective, Multicenter, Randomized Trial of the Polish Adult Leukemia Group (PALG)

Blood (2012) 120 (21): 3602.

https://doi.org/10.1182/blood.V120.21.3602.3602

Published: 2012

Journal Articles

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Blood (2012) 120 (18): 3670–3676.

https://doi.org/10.1182/blood-2012-06-438804

Published: 2012

Journal Articles

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

Blood (2012) 119 (16): 3698–3704.

https://doi.org/10.1182/blood-2011-09-378323

Published: 2012

Includes: Supplemental data

NARROW

Altered Endothelial Cells Properties and Platelets Activity in Treatment NaïVe Patients with Multiple Myeloma (MM ) and Non-Hodgkin Lymphoma (nHL): Association with Thromboembolic Complications

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Hasford Score Is Correlated with 18 Month Molecular Response for Chronic Myeloid Leukemia Patients Treated with Second Generation Tyrosine Kinase Inhibitors and It May be Useful to Differentiate Low and Intermediate Risk Patients: A Single Institution Experience

Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results

The Hasford Score Correlates with the Long-Term Molecular Response to Imatinib Treatment for Chronic Myeloid Leukemia Patients and May be Useful for Differentiating Low and Intermediate Risk Patients: A Single Institution Experience

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B

Impact of Anthracycline-Based Induction Chemotherapy on the Calreticulin, CD47 Exposure and the Percentage of Regulatory T Cells in Patients with Acute Leukemias: Preliminary Study

High Expression of Mir-15a Predicts Shorter Survival and Worse Response to Chemotherapy in Patients with Acute Myeloid Leukemia (AML)

Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA)

CD117 (c-kit) Expression On CD34+ Cells Participates In The Cytogenetic Response To Imatinib In CML Patients In First Chronic Phase

Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group

A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Daunorubicine, Cytarabine and Cladribine (DAC) Vs Daunorubicine and Cytarabine (DA) Induction Treatment in Elderly Acute Myeloid Leukemia (AML) Patients – Results of the Prospective, Multicenter, Randomized Trial of the Polish Adult Leukemia Group (PALG)

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only